Financial Contrast: iRadimed (NASDAQ:IRMD) and PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares PROCEPT BioRobotics and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
iRadimed	26.70%	23.45%	20.36%

Risk & Volatility

PROCEPT BioRobotics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Insider and Institutional Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PROCEPT BioRobotics and iRadimed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	3.27	-$95.57 million	($1.94)	-9.06
iRadimed	$83.81 million	13.47	$22.48 million	$1.79	49.31

iRadimed has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for PROCEPT BioRobotics and iRadimed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	9	3	2	2.31
iRadimed	0	3	2	1	2.67

PROCEPT BioRobotics currently has a consensus price target of $25.50, suggesting a potential upside of 45.13%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 35.95%. Given PROCEPT BioRobotics’ higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than iRadimed.

Summary

iRadimed beats PROCEPT BioRobotics on 10 of the 15 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.